LL-37 dosage chart and protocol

LL-37 has two dosage stories, and they don't overlap. The injected rows are community practice, and the wound rows are human trials of a gel or cream on ulcers, so read the source column before comparing amounts. What the peptide is and why people want it lives on the LL-37 page.

LL-37 is sold as freeze-dried powder, most often in 5 mg vials, with 10 mg vials less common. You mix it with bacteriostatic water, which is sterile water with a preservative so one vial can be drawn from more than once. The tables show the units to draw on a U-100 syringe, which holds 100 units in 1 mL, for 1, 2 and 3 mL of water. The amounts across the top are the chart's injected amounts, from community guides and one clinic page.

Because the common amounts are small, more water helps here. At 3 mL, even 100 mcg is a readable 6 units.

For any other vial, water or amount, the reconstitution calculator does the same math.

LL-37 on a wound

The only human trials of LL-37 so far put it on a wound. In the first, people with leg ulcers that hadn't healed had a gel spread on twice a week for four weeks, at 0.5, 1.6 or 3.2 mg per mL. The two weaker gels shrank the ulcers more than placebo, the strongest didn't, and the researchers reported no safety concerns over those four weeks. A larger follow-up settled on 0.5 mg per mL, with the benefit mostly in bigger ulcers, and a later diabetic foot ulcer trial used a 0.5 mg per gram cream on the same twice-a-week schedule, where new tissue built faster than on plain cream.

Those gels were made for the trials, on open wounds, under a care team. A strength in milligrams per mL on a wound doesn't tell you anything about an injected amount, which is why the two halves of the chart can't be compared.

Once a day, five days on and two off. That's the injected pattern in the community guides, and we found no study that tests it or explains the days off.

Two to four weeks, then two weeks off. It's the run described most often, again from community guides. The clinic page describes a longer, lower run of four to eight weeks.

Twice a week on a wound. That's the trial schedule for the gel and cream, set to match routine dressing changes.

No source we found names a time of day, so take that as your own call.

A mixed vial goes on a 28-day clock in the fridge the day water goes in, and at LL-37's small amounts that clock usually runs out first.

A 5 mg vial at 200 mcg five days a week would last five weeks, so it expires at 28 days with about 1 mg left. At 100 mcg, about 3 mg goes to waste. A 10 mg vial is hard to use up at these amounts, and at 200 mcg five days a week it expires with 6 mg unused. For the common pattern, the 5 mg vial is the sensible buy, and a four-week run at 200 mcg five days a week uses 4 mg of it.

These are reported experiences from community guides and clinic pages, not findings from a study of research vials.

Redness, itching or burning where you injected. It's the most common report, and people rotate the spot, add more water so each draw is less concentrated, or drop the amount.

Flushing or a hive-like reaction. Lab studies show LL-37 can set off mast cells, the cells that release histamine, so education pages tell people with allergies or a mast cell condition to be careful. People stop if it happens.

A headache. It's listed as uncommon, and most wait a few days to see whether it passes.

A flare of an inflammatory skin condition. LL-37 runs high in psoriasis and rosacea skin, so clinic pages advise against it for those conditions, and people who see a flare stop.